Shares of Aditxt, Inc. (NASDAQ:ADTX – Get Free Report) were up 8% on Monday . The company traded as high as $0.7999 and last traded at $0.7030. Approximately 336,925 shares changed hands during trading, a decline of 91% from the average daily volume of 3,791,170 shares. The stock had previously closed at $0.6510.
Wall Street Analyst Weigh In
Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Aditxt in a research report on Wednesday, January 21st. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock currently has an average rating of “Sell”.
Read Our Latest Analysis on Aditxt
Aditxt Stock Performance
Aditxt Company Profile
Aditxt, Inc is a clinical-stage biotechnology company focused on the development and commercialization of natural antimicrobial peptides and microbiome-based detection technologies. Leveraging proprietary peptide libraries, the company aims to provide novel solutions for infection prevention and control across healthcare, food safety, animal health and agricultural markets. Aditxt’s approach centers on harnessing peptides that can disrupt microbial cell membranes without promoting resistance, addressing a growing need for alternatives to traditional antibiotics and chemical disinfectants.
The company’s product offerings include contract-based microbial detection and identification services, designed to help hospitals, food processors and other regulated industries monitor contamination levels and validate hygiene protocols.
See Also
- Five stocks we like better than Aditxt
- NEW LAW: Congress Approves Setup For Digital Dollar?
- Your Bank Account Is No Longer Safe
- The day the gold market broke
- What a Former CIA Agent Knows About the Coming Collapse
- Buffett, Gates and Bezos Quietly Dumping Stocks—Here’s Why
Receive News & Ratings for Aditxt Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aditxt and related companies with MarketBeat.com's FREE daily email newsletter.
